



ASX Announcement

4th October 2013

4 per cent Dose Sales Growth in First Quarter

Sirtex Medical Limited (ASX: SRX) today announced sales of its SIR-Spheres[®] microspheres targeted radiation therapy for liver cancer grew 4.1 per cent for the quarter ended 30th September 2013 compared to the previous corresponding period. Sirtex has now recorded 37 consecutive quarters of positive growth.

Dose sales increased in the Americas by 6.6 per cent and 10.2 per cent in APAC (Asia Pacific). EMEA (Europe, Middle East and Africa) declined 5.1 per cent.

Sirtex Chief Executive Officer Gilman Wong said, “This was our second highest quarter in actual number of doses sold. However, when measured in percentage terms growth was lower than recent quarters. Dose sales in EMEA were affected by the general European economic conditions and delays in reimbursement decisions in the UK. Overall we remain confident that dose sales will continue to grow but as in the past we anticipate some fluctuations in quarter on quarter growth.

We continue to invest in and build our business in line with our *2020Vision* strategy preparing the business for the anticipated step change in growth following the completion and publication of our clinical study results starting with SIRFLOX in the latter half of calendar year 2014.”

For further information please contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511

SIR-Spheres[®] is a registered trademark of Sirtex SIR-Spheres Pty Ltd.